All In Biotech

Drug Trial Radar · NCT03384745

A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Last checked: Nov 19, 2026Latest source record: Aug 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 313 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

313

Actual

Start

Jul 31, 2018

Primary completion

Jun 20, 2019

Study completion Mar 26, 2020

Sponsor

Lead sponsor
Bond Avillion 2 Development LPIndustry
Sponsor type
Industry
Collaborators
Avillion LLP
First posted
Dec 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.

Conditions

  • Psoriasis

Interventions

  • M1095 (Sonelokimab)Drug

    M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.

  • PlaceboDrug

    Placebo contains no active drug.

  • SecukinumabDrug

    Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1Time frame: Week 12, as compared to Week 0 (baseline)

Locations

60 sites in 7 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Birmingham, Alabama

  • Investigative Site

    San Diego, California

  • Investigative Site

    DeLand, Florida

  • Investigative Site

    Sandy Springs, Georgia

  • Investigative Site

    St Louis, Missouri

  • Investigative Site

    Albuquerque, New Mexico

  • Investigative Site

    New York, New York

  • Investigative Site

    Bexley, Ohio

  • Investigative Site

    Dallas, Texas

  • Investigative Site

    Houston, Texas

  • Investigative Site

    San Antonio, Texas

  • Investigative Site

    Dupnitsa, Bulgaria

  • Investigative Site

    Sofia, Bulgaria

  • Investigative Site

    Varna, Bulgaria

  • Investigative Site

    Edmonton, Alberta, Canada

  • Investigative Site

    Surrey, British Columbia, Canada

  • Investigative Site

    Surrey, British Columbia, Canada

  • Investigative Site

    Markham, Ontario, Canada

  • Investigative Site

    North Bay, Ontario, Canada

  • Investigative Site

    Oakville, Ontario, Canada

  • Investigative Site

    Ottawa, Ontario, Canada

  • Investigative Site

    Richmond Hill, Ontario, Canada

  • Investigative Site

    Waterloo, Ontario, Canada

  • Investigative Site

    Windsor, Ontario, Canada

  • Investigative Site

    Québec, Quebec, Canada

  • Investigative Site

    Brno, Czechia

  • Investigative Site

    Náchod, Czechia

  • Investigative Site

    Nový Jičín, Czechia

  • Investigative Site

    Ostrava, Czechia

  • Investigative Site

    Ostrava, Czechia

  • Investigative Site

    Pardubice, Czechia

  • Investigative Site

    Prague, Czechia

  • Investigative Site

    Uherské Hradiště, Czechia

  • Investigative Site

    Augsburg, Germany

  • Investigative Site

    Berlin, Germany

  • Investigative Site

    Bochum, Germany

  • Investigative Site

    Darmstadt, Germany

  • Investigative Site

    Frankfurt am Main, Germany

  • Investigative Site

    Friedrichshafen, Germany

  • Investigative Site

    Hamburg, Germany

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.